Dr. Roy S. Herbst Discusses Immunotherapy in Squamous and Nonsquamous NSCLC

August 21, 2015
Roy S. Herbst, MD, PhD

Roy S. Herbst, MD, PhD, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, discusses immunotherapy in squamous and nonsquamous non-small cell lung cancer (NSCLC).

Herbst says it is quite clear that immunotherapy is becoming a new paradigm to treat these tumors. In squamous cell disease, it has risen to the second-line setting, with other trials looking at targeted therapies and combinations afterwards. The data are less clear in the nonsquamous area, however, due to the potential importance of a biomarker.

Roy S. Herbst, MD, PhD, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, discusses immunotherapy in squamous and nonsquamous non-small cell lung cancer (NSCLC). Herbst elaborates on presentations and current treatments discussed at the 17th Annual International Lung Cancer Congress® in Huntington Beach, California.